NCT00620347View on ClinicalTrials.gov

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

February 29, 2012

Study Completion Date

September 30, 2012

Conditions
Lung Cancer
Interventions
DRUG

sunitinib

sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.

Trial Locations (1)

411-764

National Cancer Center, Korea, Goyang-si

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV